Llwytho...
Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
Glioblastoma is the most common and lethal primary brain malignancy. Despite major investments in research into glioblastoma biology and drug development, treatment remains limited and survival has not substantially improved beyond 1–2 years. Cancer stem cells (CSC) or glioma stem cells (GSC) refer...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Front Oncol |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7945033/ https://ncbi.nlm.nih.gov/pubmed/33718170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.615704 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|